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Introduction
On the therapeutic front, in the race for developing tar-
geted delivery vehicles, nucleic acid-based aptamers are 
now regularly in competition with small molecules and 
antibodies  since  the  inception  of  aptamer  technology 
more than a decade ago. Aptamers (Latin aptus meaning 
“to fit”) are the functional nucleic acid ligands gener-
ated by a molecular selection process called Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX) 
and are also one of only a few classes of molecules that 
similar  to  antibodies  can  be  crafted  to  bind  to  mul-
tiple different targets (Keefe, 2008; Kanwar et al., 2010c). 
Aptamers are 20–80 base pair long single-stranded de-
oxy ribonucleic acid (DNA) or ribonucleic acid (RNA) 
oligonucleotides which are folded into unique three-di-
mensional conformations due to various intramolecular 
interactions (Kanwar et al., 2010c).
The idea of using oligonucleotides as therapeutic agents 
is not a new one; as in 1990 RNA decoys, which mimic the 
transactivating responsive (TAR) RNA of human immu-
nodeficiency  virus  (HIV),  were  shown  to  prevent  HIV 
replication  by  sequestering  the  Tat  protein  (Sullenger 
et al., 1990; Bivalkar-Mehla et al., 2010). However, among 
the various nucleic acid-based strategies employed for 
drug  discovery  research  and  therapeutics,  aptamers 
have emerged as the most promising agents for therapy 
and diagnosis, since the origin of aptamer technology 
two decades ago (Ellington, 1990; Tuerk & Gold, 1990). 
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Aptamer-mediated drug delivery enhances the therapeu-
tic efficacy due to their high specificity to the target and 
thus their affinity reduces the off-target effects or other 
unwanted side effects, commonly observed with widely 
used cytotoxic drug therapeutics. In regard to compari-
son with traditional antibodies, aptamers also known as 
“chemical antibodies,” have number of advantages such 
as (i) smaller in size and less complex with low immu-
nogenic potential, (ii) easier to synthesize and modify in 
vitro, (iii) higher affinity and specificity, (iv) structural 
flexibility enabling aptamer to bind to hidden epitopes 
which  cannot  be  targeted  by  antibodies  (Majumder, 
2009) , and (v) stronger stability and can be stored easily 
until put to use. As the use of aptamers has been extended 
from basic biology of cellular processes and gene regula-
tion  to  therapeutic  and  diagnostic  applications,  many 
patented  aptamers  are  currently  being  tested  in  clini-
cal trials and reviewed recently (Majumder, 2009). The 
resulting  outcomes  will  provide  important  validations 
of their efficacies and cost saving. The approval of an 
anti-vascular endothelial growth factor (VEGF) aptamer 
(Eyetech/Pfizer’s Macugen) six years ago, by the Food 
and Drug Administration (FDA) for treatment of age-re-
lated human macular degeneration has already proved a 
milestone for the applications of aptamer technology. In 
this review, we focus on the importance of aptamer and 
their chimerics in the field of molecular medicine. The 
review focuses on the various selection procedures along 
with the established modifications for the aptamers and 
their  chimerics.  Various  forms  of  aptamer-chimerics 
have been discussed with their therapeutic benefits and 
strategies for targeted delivery. Some of the aptamers in 
clinical trials are also listed.
Strategies for aptamer selection
For screening of aptamers, the target and the charac-
teristic of aptamers obtained must be known; a random 
pool of oligonucleotides both DNA and RNA have to be 
made for screening; the immobilized targets are used 
for screening of aptamers from the RNA or DNA pool 
(Wang, 2009). The specificity of the aptamer and its abil-
ity  to  distinguish  between  the  closely  related  species 
depends on the type of selection procedure for its isola-
tion. SELEX technique developed by Tuerk, Ellington, 
and Szostak was the first aptamer selection procedure 
(Tuerk  &  Gold,  1990;  Ellington  &  Szostak,  1992).  It 
involves selection of nucleic acid ligands which inter-
acts with specific target in a repeated binding, selection, 
and amplification of aptamers from initial library until 
the desired characteristics have been isolated. First, an 
oligonucleotide library is created which has sequences 
that  can  be  amplified  by  polymerase  chain  reaction 
(PCR). The library can be used directly for DNA-based 
aptamer  selection,  whereas  for  selection  of  an  RNA 
aptamer, the DNA library has to be converted into a RNA 
library; the known target molecule is then incubated in 
the oligonucleotide pool along with the target accom-
panied with heating and cooling to promote formation 
of stable structures. The oligonucleotides bound to the 
target are isolated and are put through repeated rounds 
of selection for obtaining the sequences with the best 
specificity.  These  sequences  are  then  cloned  in  plas-
mids,  amplified,  sequenced  and  known  as  aptamers 
(Tuerk & Gold, 1990).
In  1992,  Ellington  and  Szostak  (1992)  discovered 
another screening method for aptamers with a 10-fold 
higher affinity called as the negative SELEX, where the 
nucleotide pool was loaded on a matrix with analog of 
the target, and the unbound sequences are then used to 
incubate with the target for normal binding. Thus, aptam-
ers selected by negative SELEX had higher affinity to the 
target and could discriminate between the closely related 
targets. Negative SELEX has been used for selection of 
small molecules (Bassett et al., 2004) and proteins (Haller 
& Sarnow, 1997). Jenison and co-workers (1994) estab-
lished another screening methodology called as counter 
SELEX, for screening of small molecules’ aptamers where 
the cycles were similar to negative SELEX; however, here 
the matrices were exchanged with the analogs of the tar-
get molecules. Wang and co-workers (2003) discovered 
subtractive SELEX which removes single-stranded DNA 
or RNA sequences that can bind to nonspecific part of 
a complex target with various binding sites in order to 
obtain highly specific aptamers in the end. This process 
has extensively been used to screen aptamers for various 
cancers.
There  are  many  diagnostic  markers  and  therapeu-
tic targets expressed on the cell surface. The aptamers 
selected by SELEX may show low or no affinity toward 
them due to shielding of the aptamer’s binding domain. 
To  overcome  this,  several  groups,  as  discussed  in  the 
review by Xianbin and co-workers (2011), have reported 
the isolation of aptamers from living cells as targets such 
as cancer cells (Shangguan et al., 2006) by the process 
called as cell-SELEX. In cell-SELEX, instead of using a 
purified protein target, whole living cells are used as the 
targets. Live African and American trypanosomes aptam-
ers (Homann & Göringer, 1999; Ulrich et al., 2002) are 
some of the examples of cell-SELEX. The only drawback 
in this process is that it has to be repeated more than 25 
times (Jenison et al., 1994; Sooter et al., 2001). Capillary 
electrophoresis  (CE-SELEX)-based  selection  procedure 
developed by Bowser and Krylov groups is another revo-
lution  in  field  of  aptamer  selection  (Berezovski,  2004; 
Mendonsa  &  Bowser,  2004).  Here  the  oligonucleotide 
library is mixed with the target molecule and introduced 
into a free solution CE system. The unbound oligonucle-
otides  migrate  at  a  different  rate  than  the  oligonucle-
otides which are bound to the target. The collected bound 
sequences are then amplified by PCR and high affinity 
aptamers can be obtained only after two rounds of selec-
tion (Mendonsa & Bowser, 2004). An advancement to the 
CE-SELEX  is  the  micromagnetic  selection  (M-SELEX), 
which uses magnetic beads as solid support matrix for 
linking the target (Bruno & Kiel, 2002). More recently, 
the number of beads can be manipulated to isolate high Chimeric aptamers and targeted delivery  461
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affinity aptamers. The DNA aptamers against the light 
chain  of  botulinum  neurotoxin  type  A  has  been  iso-
lated in a single round of selection by this method (Qian   
et al., 2009).
The other forms of SELEX are covalent SELEX (Jensen 
et al., 1995), which is used to isolate aptamers that bind 
covalently to the target moiety, Toggle SELEX (White et al., 
2001) that generates aptamers with the ability of cross 
reactivity in different species, bead-based SELEX (Yang 
et al., 2002a), Tailored SELEX (Vater et al., 2003), which 
was able to regulate the size of aptamers by removing 
the fixed nucleotide sequences from the oligonucleotide 
library, and on chip SELEX (Collett et al., 2005). More 
innovatively,  Miyachi  et  al.  used  atomic  force  micros-
copy based SELEX (AFM-SELEX) which has the capabil-
ity to detect the force of affinity or adhesion between two 
molecules, to isolate anti-thrombin aptamers within just 
three rounds of selection (Miyachi et al., 2010).
With  time  the  aptamer  selection  procedures  have 
evolved due to the developing technology. Better tech-
niques have been devised to select aptamers with high 
affinity and maximum specificity to the desired target. 
However,  the  use  of  aptamers  in  diagnosis  of  biologi-
cal fluids has been limited. Thus, post-SELEX changes 
and chemical modifications have made their way into 
aptamer technology due to a continuous need of stability 
and efficient activity.
Established aptamer modifications to  
overcome aptamer instability
The  use  of  modified  nucleotides  has  been  the  most 
commonly  approached  method  to  overcome  aptamer 
instability.  Precise  site-specific  modifications  facilitate   
engineering  of  aptamers  for  delivery  into  target  cells 
with enhanced specificity. The need for modification is 
justified by functional optimization, truncation, or multi-
merization of aptamers which has enhanced the binding 
efficacy and stability. Various linkage designs, modifica-
tion strategies, and conjugation approaches are preva-
lent in aptamer technology. The various modifications   
of nucleotides, mainly the chemical ones, are compatible 
with the enzymatic steps of in vitro selection procedure, 
introduced  either  at  phosphate/ribose  backbone  or  at 
the nucleobases (Keefe & Cload, 2008).
Chemical modifications in aptamers
Replacement of DNA phosphate backbone by phospho-
rothionate  enhanced  stability  against  nucleases  and 
the  cell  viability  of  aptamers  (Eckstein  &  Gish,  1989). 
However, most prominent modification of aptamers is 
derivatization  of  2´-ribose,  as  this  position  conferred 
stability  of  most  RNA  aptamers  (Yang  et  al.,  2002b). 
Several other different approaches have been reviewed 
for improving aptamer stability in biological fluids due to 
the sensitivity of both DNA and RNA aptamers to nucle-
ases which limits their therapeutic and diagnostic poten-
tial (Kusser, 2000). Most of these approaches rely on the 
incorporation of nucleotides carrying modifications of 
either sugar residues (2´-F, 2´-NH2 (amino), 2´-O-methyl, 
2´-O-methoxyethyl and 2´-O-dimethyl allyl) (Green et al., 
1995; Ruckman et al., 1998) of the phosphate (phospho-
rothioate  and  methyl  phosphonate)  (Eckstein  &  Gish, 
1989) or of the nitrogenous base [propenyl, 5-(N amino-
alkyl) carbomoyluracil, methyl, trifluoromethyl, phenyl 
and 2-thiopyrimidine] (Lin et al., 1996).
Pyrimidines are modified at fifth position to enhance 
the stability of the aptamer with iodide (I), bromide (Br), 
chloride (Cl), amino (NH3), azide (N3) (Kirschenheuter, 
1997) and 2´ position with amino (NH2), fluoro (F), and 
methoxy (OCH3) (Barry et al., 1996). These modifications 
also provide nuclease resistance. The 2’ sugar modifica-
tions, fifth position pyrimidine modification, substitution 
of 4-thiouridine, substitution of 5-bromo or 5-iodouracil, 
backbone modification, methylations and unusual base 
pairing combinations such as isobases, isocytidine, and 
isoguanodine (Sampson, 2003), and 3’ capping (Kasahara 
Y, 2010) are other forms of modifications which provide 
thermal  stability  and  nuclease  resistance  to  aptamers 
(Figure 1). The SELEX protocol also offers possibility of 
further diversity during selection and enrichment where 
modifying the aptamers is much easier when compared 
to post-SELEX methods (Sampson, 2003).
Aptamers with photolabile protecting groups offer a 
possibility for the spatiotemporal regulation of aptamer 
activity with control over activity of the target molecule. 
Using this modification the aptamer can be activated or 
deactivated by specific light intensity (Mayer et al., 2005; 
Heckel et al., 2006). Hence aptamers can be modified to 
fluoresce at their fifth position by chemical or enzymatic 
synthesis  (Sengle,  2000).  The  chemical  modifications 
are induced to increase the half life and stability of the 
aptamers.  The  modified  aptamers  can  be  obtained  by 
spiegelmer technology, which is also known as mirror 
image SELEX. In this method, aptamers of chiral target 
from naturally occurring dextrorotatory oligonucleotide 
pool are screened and from them the complementary lev-
orotatory oligonucleotide is synthesized called as spiegel-
mers.  These  spiegelmers  have  equivalent  capability  as 
the initial aptamer to bind with high affinity to the target 
(Wlotzka et al., 2002) and the chemical modification is 
induced later as the levorotatory molecule with chemical 
modifications cannot be recognized by SELEX enzymes; 
this molecule can recognize the target with more specific-
ity and has better stability (Eulberg & Klussmann, 2003).
Chimeric aptamer: an insight
There  is  an  increasing  enthusiasm  for  generating  new 
and  more  potent  cell  internalizing,  highly  specific 
aptamers with greater stability and nuclease resistance. 
Recombination is a powerful evolutionary force and it 
is a known fact that the protein segments are routinely 
recombined to engineer various chimeric proteins with 
novel  functions.  Aptamer  diversity  is  required  for  the 
development of more established and better character-
ized aptamers; thus the need for modification and chi-
merization arises. Chimerization started with the idea of 462  J.R. Kanwar et al.
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creating antibodies for any potential target (Riechmann 
et al., 1988; Russell et al., 1992). The constant need for 
higher specificity, stability, and effectiveness motivated 
better  synthesis  procedures  over  time.  Similarly  to 
antibodies  and  proteins’  chimerization,  aptamer  chi-
merization has been carried out for characterizing and 
diversifying them over a long period of time (Goldstein 
et al., 1995; Song et al., 2005).
Chimerization of aptamers refers to its combination 
with  another  aptamer,  biomacromolecule(s)  and/or 
compounds where the functional capability of the chi-
mera is a combined factor of aptamer as well as the other 
biomacromolecules and/or compounds used in combi-
nation (Burke & Willis, 1998).
Chimeric  aptamer  approach  aims  to  combine  two 
aptamers  or  an  aptamer  with  another  non-aptamer 
moiety (biomacromolecules, drug, or dyes), where one 
molecule engages with the target and the other has a func-
tional effect on the target molecule. When two aptam-
ers or an apatmer with another biomacromolecule are 
added together, either through natural recombination or 
chemical engineering, it is difficult to know beforehand 
whether the joining may diminish the activity of one or 
both  of  the  recombining  partners;  hence,  chimeriza-
tion was considered as a challenging procedure (Burke 
& Gold, 1997a; Burke & Willis, 1998). However, with the 
progress of research in this field as discussed here, it is 
very  clear  that  chimeric  aptamers  are  not  only  highly 
stable and efficient in activity but are also able to deliver 
drug loads.
Selection of the aptamer chimeras
The selection of chimeric aptamer over the parent type 
aptamer  needs  efficient  comparison  between  them  in 
terms of specificity of binding and the binding affinity. 
Within a chimeric SELEX, two or more different libraries 
are used for the production of chimeric aptamers with 
more than one wanted feature or which are able to func-
tion in different ways. Each of the parent libraries will be 
selected first for a distinct feature. The selected biomol-
ecules are then fused in such a way that they acquire sev-
eral properties (Burke & Willis, 1998). Chimeric SELEX 
method simulates random recombination among func-
tional aptamers derived from nucleotide population with 
70 to 80 positions of random sequences as a mean to gen-
erate aptamers with novel functions. Another method to 
obtain multifunctional aptamers is multiple SELEX; two 
aptamers with specificity toward coenzyme-A, chloram-
plenicol  or  adenosine  could  be  fused.  This  selection 
strategy was applied to obtain a suitable chimera capable 
Figure 1.  Figure shows the various modifications made in an aptamer to increase its stability and functionality. The common modifications 
made in the ribose residue of the sugar-phosphate backbone are incorporations of 2´-fluorine (F) and 2´-amino group (NH2), in the 
phosphate group of the sugar-phosphate backbone are incorporation of phosphorothioate and methyl phosphonate. The modification 
made in the nucleotide base includes incorporation of 5´- bromide (Br) and amino group (NH2) (Cheung et al., 2010). The 3´-capping 
of the aptamer sequence is also another form of modification, which helps in increasing the stability of aptamer and its prevention from 
nuclease degradation (Kasahara et al., 2010). (See colour version of this figure online at www.informahealthcare.com/bmg)Chimeric aptamers and targeted delivery  463
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of binding both the targets. This will have several appli-
cations such as catalysis, therapeutics, structure studies, 
etc. (Burke et al., 1997b; Burke & Willis, 1998) In another 
work, two nucleic acid pools of 40 and 60 units were used 
to screen aptamers for cibacron blue and cholic acid. 
After five to six rounds of selection, the aptamers were 
fused and the ones with the ability to bind both cibacron 
blue  and  cholic  acid  were  obtained.  It  was  observed 
that the chimeric aptamer could bind either to cibacron 
blue and could be eluted by cholic acid or could bind to 
cholic acid and be eluted by cibacron blue; these results 
highlighted the importance of allosteric interactions in 
mechanism of chimerism (Wu & Curran, 1999).
Zinc fingers have diverse functions in a cell, mainly 
dealing  with  interactions  with  DNA,  RNA,  or  proteins 
and play a major role in the regulation of gene expres-
sion (Laity et al., 2001). Work done in this field compared 
interaction of several different zinc finger proteins with 
RNA1 (a high affinity aptamer for zinc finger) where, site-
directed mutagenesis in RNA1 was used to identify key 
and structural elements in RNA1 involved in the forma-
tion of high affinity interactions with a broad range of 
zinc fingers (Lu et al., 2003). The modified forms, RNA1, 
RNA21, and RNA 22, were compared to characterize RNA 
molecules with high affinity for a set of zinc fingers (Weiss 
et al., 2010). Such studies help in identifying the most 
specific aptamer for a target which has several applica-
tions such as coordinated release of protein on a specific 
time  scale  or  release  in  a  specific  cellular  location.  A 
similar  work  describes  isolation  of  2´-fluoro  (2´-F)-
substituted RNA aptamers that bind to streptavidin with 
high affinity. After selection of aptamer SA19 (specific 
for streptavidin), it was mutated by DPTP [6-(2-deoxy-β- 
D-erythropentofuranosyl)-3, 4-dihydro-8H-pyrimido-(4, 
5C) (1, 2) oxamine-7-one-5´-triphosphate], a nucleotide 
analog. The 2´-F-pyrimidine containing RNA transcripts 
from various mutagenesis cycles were analyzed by sur-
face  Plasmon  resonance  (SPR)  to  verify  the  abolition 
of binding to streptavidin. Metal transporting ATPases 
CopA and CopT sequences were inserted downstream 
of SA19 aptamer to form chimeric SA19-CopA or SA19-
CopT. Their properties were then compared with SA19 
unmodified  aptamer  for  characterization  of  binding 
affinity and specificity (Alaoui et al., 2002). In the study 
done by McNamara and co-workers, even though the first 
generation prostrate specific membrane antigen (PSMA) 
aptamer/  polo-like  kinase  1(Plk1)-siRNA  (A10-Plk1) 
chimera inhibited tumor growth, it lacked the ability to 
be systemically administered (McNamara et al., 2006). 
Thus, in continuation of their work, a second generation 
of PSMA-Plk1 chimeras was designed to facilitate chemi-
cal synthesis, to enhance silencing activity, specificity, 
and to enable modifications to optimize in vivo kinetics. 
The changes made to the first generation chimeras to 
facilitate chemical synthesis were to reduce the aptamer 
size from 71 nucleotides to 39 nucleotides and a 2´-F was 
added to the longer strand and the shorter strand was 
unmodified.  To  increase  the  silencing  activity,  several 
chimeras were engineered, ones with an overhang at 3´ 
end of siRNA duplex, ones with a wobble base at 5´ end of 
guiding strand of siRNA, ones where the passenger and 
the guide strand were swapped, and ones with a stem 
loop. Then, the binding of optimized chimeras to PSMA 
expressing  cells  was  tested;  all  chimeras  had  retained 
the binding ability confirming that modifications made 
to first generation did not alter binding or specificity. To 
determine the enhancement of silencing activity of the 
chimeras for gene-specific silencing, a quantitative real 
time polymerase chain reaction (qRT PCR) was used and 
it was confirmed that siRNA portion of chimera enhanced 
Plk1  silencing,  most  active  were  swap  and  stem-loop 
chimeras. Finally, the effect of chimeras on growth and 
survival of prostate cancer cells was tested and it was 
found  that  second  generation  chimeras  inhibited  cell 
growth and proliferation at a lower concentration than 
the first generation chimeras (Justin et al., 2009). Even 
though they are engineered well and have more capabil-
ity, the chimeric aptamers are as prone to degradation as 
an unmodified aptamer. However, there are some mol-
ecules such as locked nucleic acids (LNA’s) (Lebars et al., 
2007), which when incorporated into the chimeras pro-
vide a higher grade of stability and specificity and thus 
help in the selection of the chimeras by giving them an 
additional advantage over the parental types.
LNA-based modifications
Both DNA and RNA oligonucleotides are highly suscep-
tible  to  degradation  by  nucleases.  Thus,  the  potential 
applications and the usage of aptamers in drug delivery 
are limited by the susceptibility of aptamers to degra-
dation  by  intracellular  nucleases.  To  further  improve 
the  stability  against  nucleases  and  to  overcome  this 
limitation, the use of non-natural bases, such as LNA, 
were used (Orum & Wengel, 2001; Petersen & Wengel, 
2003; Hernandez et al., 2009;). The LNA comprises of a 
new class of bicyclic high affinity analogs (2´-O, 4´-C-
methylene-β-D-ribofuranosyl  nucleotide)  in  which 
furanose  ring  of  ribose  sugar  is  chemically  locked  in 
an  RNA  mimicking  conformation  by  introduction  of 
2´-O,4´-C-methylene bridge. These impart high degree 
of thermal stability when hybridized with their DNA and 
RNA target molecule (Figure 2). A specific feature of LNA 
is  that  they  induce  the  neighboring  DNA  to  adopt  an 
A-type conformation in a DNA–RNA duplex. Since LNA 
hybrids are not compatible with standard enzymes that 
are used in SELEX, only post-SELEX is followed for their 
selection (Barciszewski et al., 2009). The introduction of 
LNA into aptamers renders the molecule highly resistant 
toward nuclease degradation. Significant stabilization of 
aptamers has been achieved by introduction of LNA at 
various positions of oligonucleotides. There are mainly 
three types of LNA: antigenic LNA, antisense LNA, and 
LNA aptamers. Immense work has been done with LNA 
hybrid  aptamers,  such  as  in  a  39-mer  oligonucleotide 
TTA1 (RNA aptamer); LNA was introduced which exhib-
ited significant stem stabilization and improved plasma 464  J.R. Kanwar et al.
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stability of the aptamer while maintaining high binding 
affinity to the target (Barciszewski et al., 2009). Another 
study showed that LNA was used for modification of R06 
aptamer to generate stable hybrid with improved bind-
ing affinity to form kissing complexes with the target with 
higher nuclease resistance (Lebars et al., 2007). Recently 
invented LNA nucleotides have been shown to be effective 
both in and without combination of taxol for inhibiting 
expression of survivin thereby leading to tumor growth 
inhibition  when  compared  to  LNA  nucleotides  alone 
(Kanwar et al., 2010a). Survivin is a member of inhibitor 
of apoptosis (IAP) family of proteins that has a dual role 
in cell division (mitosis) and apoptosis (Kanwar et al., 
2001; Altieri, 2003; Baratchi et al., 2010; Kanwar RK et al., 
2010; Kanwar, 2010a). It is known to be over-expressed in 
most of the tumors and has become recently an attrac-
tive target for novel anticancer therapies (Kanwar et al., 
2001; Altieri, 2003; Baratchi et al., 2010; Kanwar RK et al., 
2010; Kanwar et al., 2010a). A set of researchers prepared 
locked nucleic acid nanoparticle conjugate (LNP’s) by 
adding thiol-terminated LNA oligonucleotides to a solu-
tion containing gold nanoparticles (AuNPs) in phosphate 
buffer  and  also  prepared  DNA-modified  nanoparticle 
analogs for comparative study by using antisense DNA 
and LNA, and they found out that LNP’s were more stable 
and induced a better relative decrease in survivin expres-
sion  (Seferos  et  al.,  2007).  In  another  work,  chimeras 
were synthesized by surface plasmon resonance (SPR) 
from 64 LNA/2´-o-methyl sequence to all possible com-
bination in a kissing RNA-aptamer loop complementary 
to  epsilon-nucleotide  loop  of  TAR  element  of  HIV-1. 
Following which a chimera of higher specificity than the 
parent RNA aptamer was obtained and one of the chime-
ras also showed inhibition of TAR-dependant luciferase 
expression in a cell assay (DI Primo et al., 2007). The LNA 
incorporations have successfully changed the scenario of 
aptamer instability and their effectiveness has been well 
established with time.
In spite of being able to incorporate several beneficial 
properties into the chimeras, their delivery is yet another 
necessary stage which plays a key role in their action.
Various types of aptamer chimeras and their 
functional applications in therapeutics
There are many possible types of chimerization such as 
aptamer–siRNA  chimeras,  aptamer–enzyme  chimeras, 
and aptamer–aptamer chimeras (Table 1 and Figure 3). 
Aptamer  technology  has  evolved  in  a  multidirectional 
fashion finding importance and playing essential roles in 
fields of biosensing, imaging, drug delivery, and modern 
molecular medicine for therapy for various diseases and 
disorders.
Aptamer–biomolecule conjugate
A  recent  work  done  on  aptamer–antibody  chimera 
provides  an  effective  methodology  for  sensitive  and 
specific identification of a pathogenic bacteria Listeria 
monocytogenes in food. Aptamer A-8, specific for inter-
nalin  A,  an  invasion  protein  of  L.  monocytogenes  was 
used  in  fiber  optic  sensor  together  with  biotinylated 
P66 antibody in a sandwich format for the detection of 
L. monocytogenes from food samples (Ohk et al., 2010). 
Figure 2.  The structure of the locked nucleic acid molecule is shown in Figure 3. The reason for its stability is due to the presence of 
an additional bond between the hydrogen on the 4th carbon and the oxygen atom on the 2nd carbon, which also gives the molecule a 
locked structure and makes it more resistant to thermal degradation. The incorporation of the LNA molecules into the aptamer is also 
shown which stabilizes the structure, and finally the LNA-incorporated aptamers are loaded onto a nanoparticle for target delivery (DI 
Primo et al., 2007; Lebars et al., 2007; Seferos et al., 2007; Barciszewski et al., 2009). (See colour version of this figure online at www.
informahealthcare.com/bmg)Chimeric aptamers and targeted delivery  465
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Many bacterial strains have become drug resistant with 
the  overexposure  to  antibiotics  worldwide.  Bacterial 
infection is a major health concern and demands more 
advanced treatments, such as use of nanotechnology or 
nanomedicine (Mathews et al., 2010). Chimeric aptam-
ers can play potential role in antibacterial diagnostics 
and therapeutics due to obvious benefits over traditional 
antibacterial medicines. An aptamer–aptamer chimera 
has  been  developed  recently,  containing  adenosine 
DNA aptamer and malachite green (MG) RNA aptamer 
joined  by  bridging  strands  that  has  complementary 
sequences to both aptamers. In the presence of adenos-
ine,  aptamer  strand  binds  to  adenosine  leaving  fewer 
numbers of complementary base pairs between aptamer 
and bridge strand, which is less stable, and results in 
release of bridge strand and observance of fluorescence 
of malachite green (XU & LU, 2010). The fluorescence 
can be detected by eye and no sophisticated instrument 
is required for this. Such chimeras can be used very effi-
ciently in real time detection and quantification of small 
analytes. Work done by another group shows an example 
of aptamer–enzyme chimeras, the aptamer against trans-
ferrin receptor was isolated and coupled to a dephos-
phorylated α-L-iduronidase enzyme. It was shown that 
the aptamer–enzyme chimera was successfully taken up 
by receptor-mediated endocytosis and restored activity 
in  cultured  fibroblasts  lacking  this  enzyme  (Chi-Hong   
et al., 2008).
Aptamer–biomacromolecule conjugate
The most established and best-characterized chimeras 
are  the  aptamer–siRNA  chimeras.  This  interesting  and 
recent innovative approach aims to use the aptamers in 
siRNA therapeutics. Though work has been done with 
these chimeras (Eli, 2010; Zhou et al., 2011), yet most 
prevalent  one  targeted  for  therapy  is  against  PSMA,  a 
Table 1.  Chimeric aptamers and their action.
S. No. Chimera type Specific to In vitro/in vivo Action Trial state Reference
1. Aptamer–antibody (Apt-
A8-P66 Ab)
Internalin 
A of L. 
monocytogenes
L. monocytogenes Detection of L. 
monocytogenes in 
food samples
Pre-clinical Ohk et al. (2010)
2. Aptamer–aptamer (DNA 
Aptamer–RNA malachite 
green aptamer)
Adenosine Cell free assay Detection of 
adenosine
Pre-clinical XU and LU (2010)
3. Aptamer–enzyme 
(antitransferring aptamer-
α-L-iduronidase)
Transferrin In vitro-mouse fibroblast 
Ltk cells
Restores activity 
in cells lacking the 
enzyme
Pre-clinical Chi-Hong et al. 
(2008)
4. Aptamer–siRNA (A10 
aptamer–siRNA)
PSMA In vitro-LNCaP cells Inhibits expression of 
PLK1 and BCl2
Pre-clinical Zhou and Rossi 
(2010)
5. Aptamer–siRNA (PLK1 
aptamer–siRNA)
PLK1 In vitro-Human MM 
cells− H2452, H2052, H28, 
and 211H. NDHF cells
Inhibits expression of 
PLK1
Pre-clinical Kawata et al. 
(2010)
6. Aptamer–siRNA (PSMA 
apt-smg1/siRNA)
PSMA In vitro-CT26, B16 In  
vivo-athymic nude mice
Inhibiting nonsense 
mediated mRNA 
decay
Pre-clinical Pastor et al. (2010)
7. Aptamer–siRNA (PSMA 
apt-siRNA)
PSMA In vitro-PC-3, LNCaP, 
HeLa. In vivo-athymic 
nude mice
Inhibits expression of 
PLK1
Pre-clinical McNamara et al. 
(2006)
8. Aptamer–siRNA PSMA In vitro-HeLa, N12-E, 
human cervical cancer
Boron neutron cancer 
therapy
Pre-clinical Shaw et al. (2008)
9. Aptamer–siRNA (PSMA 
apt-shRNA-Dox-PEG-PEI)
PSMA In vitro-PC-3, LNCaP Inhibits expression of 
BCL-xl
Pre-clinical Kim et al. (2010)
10. Aptamer-siRNA (anti-TAR 
apt(R06)–siRNA)
TAR Cell free assay Inhibits TAR 
expression
Pre-clinical Lebars et al. (2007)
11. Aptamer-siRNA (anti-
gp120 apt–siRNA)
Gp120 (HIV) In vitro-HEK293, CEM, 
PBM cells donors.
Inhibits HIv-1 P24 
production and gp120 
expression
Pre-clinical Zhou et al. (2008)
12. Aptamer–miRNA 
(Aptamer–pri-miRNA)
Pri-miRNA In vitro-HeLa Modulating pri-
miRNA processing
Pre-clinical Katoh and Katoh 
(2008)
13. Aptamer–NRTI HIV1-RT In vitro-lymphoid cells 
lines
Inhibition of DNA 
polymerization by 
HIV1-RT
Pre-clinical Held et al. (2006)
14. Aptamer–thrombin Mercury (2+) 
and Lead (2+)
Cell free assay Detection of Hg(2+), 
Pb(2+)
Pre-clinical Smirnov and 
Shaffer (2000)
15. Aptamer–aptamer ATP Cell free assay Detection of ATP Pre-clinical Chen et al. (2008)
PSMA, prostate specific membrane antigen; LNCaP, androgen sensitive human prostate carcinoma; PLK1, polo like kinase1; smg1, gene 
coding for serine/ threonine-protein kinase SMG1; HeLa, human cervical cancer cells; HEK293, human embryonic kidney 293 cells; 
CEM, human lymphoblastic cells; Human MM cell, human multiple myeloma cells; NDHF cells, normal human dermal fibroblast cells; 
PBM cells, peripheral blood mononuclear cells.466  J.R. Kanwar et al.
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cell-surface receptor over-expressed in prostate cancer 
cells and tumor vascular endothelium (McNamara et al., 
2006). Some of the work done on PSMA is summarized 
here. An aptamer–siRNA chimera was developed where 
the  aptamer  portion  of  the  chimeras  mediated  bind-
ing to PSMA, whereas the siRNA portion targeted the 
expression  of  tumor  survival  genes  polo-like  kinase  1 
(Plk1)17  and  Bcl-2.  The  chimera  effectively  delivered 
the  associated  siRNA  specifically  to  LNCaP  prostate 
cancer  expressing  PSMA  cells  and  triggered  apoptosis 
that resulted in cell death both in culture and in a pros-
trate tumor xenograft model (McNamara et al., 2006). In 
another study 2´-F modified anti-PSMA aptamer (A-10) 
was covalently linked to sense strand of 21-mer siRNA 
hybridized  to  21-mer  antisense  strand,  the  resulting 
chimeric was shown to selectively internalize into cells 
expressing  PSMA  and  inhibit  expression  of  targeted 
tumor survival genes (Plk1 and Bcl2) aptamer. A portion 
of PSMA-A10PLK1 chimera was truncated from 71 to 39 
nucleotides, while still maintaining high binding affinity; 
structural changes were made to siRNA enabling efficient 
incorporation (Zhou & Rossi, 2010; Zhou et al., 2011).
In a similar work, a DNA-chimeric siRNA was gen-
erated against Plk1, which was more stable in human 
serum than nonchimeric siRNA and the chimeric Plk1-
siRNA  inhibited  malignant  mesothelioma  (MM)  cell 
proliferation through the induction of apoptosis in vitro. 
This DNA-modified siRNA chimera was constructed by 
substituting six ribonucleotides at the 5´ end of the guide 
strand with the cognate de-oxyribonuclotides; thus the 
siRNA could be protected from RNAse or nuclease degra-
dation by partial substitution of ribonucleotides with de-
oxyribonucleotides (Kawata et al., 2010). Another recent 
work describes an alternative approach in which expres-
sion  of  new  and  potent  antigens  is  induced  in  tumor 
cells by inhibiting nonsense-mediated messenger RNA 
decay (NMD). In this study, PSMA aptamer-smg1/siRNA 
chimera  was  made  to  stimulate  protective  antitumor 
immunity and it was suggested that the dose treatment 
of aptamer–siRNA chimeras can be further optimized to 
inhibit tumor (Pastor et al., 2010). To down regulate gene 
expression through tryptophanase (TNA) interference in 
combination with aptamer therapy a 21-nucleotide double 
stranded (ds) siRNA and fluoro-modified aptamers were 
used. Substituting a borane phosphate for part of natural 
phosphodiester bond in RNA allows the use of siRNA to 
persist in cells for longer than unmodified siRNA and the 
boron neutron capture therapy (BNCT) to specifically kill 
Figure 3.  Illustrations of the various types of chimeric forms of aptamers established, such as the aptamer–antibody (Ohk et al., 2010), 
aptamer–protein (Zhou & Rossi, 2010), aptamer–siRNA (Kawata et al., 2010) (Pastor et al., 2010), aptamer–miRNA (Lunse, 2010), and the 
aptamer–aptamer (Held et al., 2006) chimeras. The use of sticky bridges is also depicted which helps in binding of the aptamer moiety to 
the siRNA and the miRNA’s due to presence of complementary regions on the sticky loop for both siRNA/miRNA and the aptamer. The 
aptamer conjugates are then shown to conjugate with the nanoparticles binding to the target cells by the interaction of aptamer–receptor 
interaction, and finally the nanoparticles are internalized inside the target cells and results in release of siRNA, miRNA, protein, or the 
aptamer molecule, respectively (Lundberg et al., 2007; Farokhzad et al., 2004; Khaled et al., 2005; Alonso et al., 1994; Molpeceres et al., 
1999). (See colour version of this figure online at www.informahealthcare.com/bmg)Chimeric aptamers and targeted delivery  467
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prostate cancer cells (Shaw et al., 2008). Work done with 
aptamer–siRNA  on  other  targets  included  use  of  anti-
TAR aptamer (R06) as regulator of TAR-dependant gene 
expression to benefit affinity and resistance to RNAses 
(Duconge  &  Toulme,  1999).  The  binding  between  the 
aptamer and target occurs in form of kissing interactions 
as R06 has a hairpin RNA loop complementary to TAR 
and guanosine-adenosine (G-A) combination, stacking 
interactions  and  hydrogen  bonds  at  stem/loop–loop 
junction aids in stability of complex (Duconge & Toulme, 
1999; Lebars et al., 2007). Modification of R06 by N3´ to 
P5´ phosphoramidate, 2´-omethyl, hexitol nucleic acid, 
improved  nuclease  resistance;  however,  there  was  no 
increase in binding affinity (Lebars et al., 2007). A novel 
dual  inhibitory  functional  anti-gp120  aptamer–siRNA 
chimera, in which both aptamer and siRNA have potent 
anti-HIV activities has also been developed (Zhou et al., 
2008). In this approach, anti-gp120 aptamers (A-1 and 
B-68) were used which inhibited HIV-1 P24 production 
and provided more potent inhibition of HIV infectivity. 
The aptamer and siRNA were linked via sticky sequences 
consisting of 16 nucleotides at aptamer 3´ end, which 
were  complementary  to  16  bases  on  one  of  the  two-
siRNA strands (Zhou et al., 2008; Zhou et al., 2011). The 
sticky bridge base approach offered a major advantage in 
both the chemical synthesis and the opportunity to mix 
and match the aptamer with different siRNAs in a non-
covalent fashion.
Micro RNAs (miRNAs) are short sequences of nucle-
otides occurring naturally in cells that are important 
in  regulating  gene  function  and  expression  of  path-
ways by controlling the amount of miRNA that binds 
to a gene and is possible to upregulate or downregu-
late the genes (Vella & Slack, 2005). The miRNAs can 
be targeted to the stem cell signaling components or 
epithelial to mesenchymal transition (EMT) regulators 
and aptamers can be utilized for directing the applica-
tion of miRNA as a potent therapeutic (Katoh & Katoh, 
2008). Various miRNAs have tumor suppressing activity 
and may play a vital role in other disease prevention or 
development; hence, they are important in diagnosis 
and therapy of human diseases (Silahtaroglu A, 2010; 
Kanwar, 2010b). Isolation and characterization of RNA 
aptamers that specifically binds to primary transcript 
miRNA to the apical loop domain of the pri-miRNA has 
been done. The results showed that aptamers could be 
applied as agents for modulating pri-miRNA process-
ing and also as tools for understanding the mechanism 
(Lunse, 2010).
Aptamer–drug conjugates
A  work  done  with  aptamer–siRNA  chimera  dealt  with 
the  development  of  a  chimeric  molecule  using  PSMA 
aptamer with small hairpin RNA (shRNA) against anti-
apoptotic  factor  BCL-XL  and  drug  doxorubicin  (dox). 
Their conjugation into a polyplex of polyethyleneimine-
polyethyleneglycol (PEI-PEG) was done for target-spe-
cific delivery, synergistic, and selective cancer cell death 
by  aptamer  mediated  co-delivery  of  doxorubicin  and 
shRNA was achieved by activation of an intrinsic apop-
totic pathway in prostate cancer cells, both in vitro and 
in vivo (Kim et al., 2010). Nucleotide analog reverse tran-
scriptase inhibitors (NRTI), for example, Azidothymidine 
triphosphate  (AZTTP)  and  2´,  3´-Dideoxy  cytidine-
5´-triphosphate  (ddCTP),  are  chain  terminators  that   
prevent completion of viral genome replication following 
their incorporation in reverse transcriptase (RT) during 
DNA polymerization (Enomoto L, 2011). A recent work   
tested aptamers in combination with NRTI, which dis-
played significant synergy for inhibition of DNA polym-
erization by HIV1-RT, where the RNA and DNA aptamers 
were generated by SELEX, specific for HIV-1 RT (Held 
et al., 2006).
Aptamer–dye conjugates for nanodiagnostics
In  presence  of  mercury,  Hg(2+)  and  lead,  Pb(2+)  a 
thrombin-binding aptamer containing six thymine and 
nine guanine units changes into a hairpin like structure 
(Smirnov  &  Shaffer,  2000),  thus  thymine-containing 
thrombin-binding aptamers can be used to target mer-
cury, Hg(2+) (Miyake et al., 2006). According to a recent 
chimeric approach, the domains of two aptamers can 
be linked, one that engages a fluorophore for signaling 
and other that binds a nonfluorescent target, into one 
sequence  in  such  a  way  that  the  binding  of  the  non-
fluorescent target will strengthen or reduce the affinity 
of the chimeric aptamer for fluorophore. The signal is 
produced as a result of the aptamer–fluorophore asso-
ciation or separation that is accompanied by a change 
in fluorescence intensity. Similarly, multiple targets can 
be simultaneously reported by using two or more struc-
ture substituting aptamers labeled with different fluoro-
phores, for example, the adenosine tri-phosphate (ATP) 
binding aptamer, ATP1.1, can form a signaling duplex 
with FDNA1 (carrying fluorescein) and QDNA2, while the 
guanosine tri-phosphate (GTP) binding aptamer, GTP1.2, 
can form a signaling duplex with FDNA2 (carrying cy3) 
and QDNA2. The resulting mixture can generate a real-
time signal for both ATP and GTP when both reporters 
are mixed into a single solution (Nutiu & Li, 2005).
To  facilitate  the  diagnosis,  identification,  and  study 
of mechanism of various diseases and pathways, highly 
efficient  aptamer-based  detection  systems  have  also 
been validated. To detect the presence of cocaine in sam-
ples, the functionalized quantum dots (QDs) consisting 
of two subunits of aptamers were used, where one was 
linked to QD and the other was specific to cocaine and 
formed  the  cocaine–aptamer–aptamer–QD  complex  in 
presence of cocaine, where cocaine induced a confor-
mational change in the complex leading to change in 
QD behavior (Freeman, 2009; Zhang & Johnson, 2009). 
Detection of ATP has been achieved by adsorption and 
covalent coupling of ATP-binding DNA aptamers onto 
cellulose, where the properties of cellulose enhance the 
DNA  aptamer  activity  (Su  et  al.,  2007).  Another  study 
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ATP using the following three different oligonucleotides 
in a complex; (i) A 3´-biotin modified DNA specific to 
streptavidin bound to streptavidin coated on QDs; (ii) 
3´-cy5  labeled  DNA;  and  (iii)  an  aptamer  specific  to 
ATP.  In  the  absence  of  ATP,  all  three  oligonucleotides 
formed a stable complex and thus normal fluorescence 
was observed, whereas, in the presence of ATP, the 3´cy5 
labeled  DNA  got  dissociated  from  the  complex  and 
the fluorescence intensity changed (Chen et al., 2008). 
Angiogenin is a potent angiogenic protein which has a 
role in tumor angiogenesis and RNA transcription (Xua 
et al., 2002). Cellular internalization of angiogenin was 
investigated  by  a  highly  specific  fluorophore-labeled 
aptamer for angiogenin by real-time protein imaging in 
living cells using confocal laser scanning microscopy (Li, 
2008).  Other examples include detection of C-reactive 
protein (CRP) which is highly expressed in inflammation; 
it also serves as a biomarker (Tsimikas et al., 2006). The 
detection was based on a sandwich format where a bioti-
nylated RNA aptamer specific to CRP was immobilized 
on  streptavidin-coated  magnetic  beads;  the  modified 
beads were incubated with CRP solution and recoupled 
with same biotinylated aptamer. After the binding, the 
extent of affinity was evaluated by addition of enzymatic 
substrate, which was transformed into an electroactive 
product and the detection of the enzymatic reaction was 
done by differential pulse voltametry (DPV) (Centi et al., 
2010).  Super  paramagnetic  iron  oxides  (SPION)  were 
used as nanoparticles; A10 RNA aptamer against PSMA 
was tagged with doxorubicin (dox) and covalently bound 
to  the  nanoparticles,  which  induced  magnetization 
inside a magnetic field (Wang et al., 2008).
For imaging applications, the aptamers can be bound 
to imaging agents such as fluorophores, QDs, magnetic 
resonance imaging (MRI) agents, magnetic nanoparti-
cles, etc. The method of visualization mainly depends on 
the type of nanoparticle used or the modifications made 
in the aptamer and aptamer chimerics which aid in their 
detection. In a recent work, the AS1411 aptamer specific 
to  nucleolin  protein  was  conjugated  to  cobalt-ferrite 
nanoparticles  surrounded  by  fluorescent  rhodamine 
within a silica shell and was incorporated into cancer 
cells for imaging. The imaging was based on magnetic 
fluorescence  nanoparticles  inside  cancer  cells  by  MRI 
(Hwang et al., 2010). Theophylline is a bronchodilator 
used  in  case  of  asthma,  bronchitis,  and  emphysema; 
since its overdose can lead to toxic effects, it is important 
to detect its levels in body. The AuNP were conjugated to 
theophylline-specific aptamer. In the presence of theo-
phylline, the aptamer dissociates from AuNP leading to 
an aggregation of AuNP and an increase in AuNP plas-
monic peak. The observed intensity enables the detection 
of theophylline (Chavez et al., 2010). In another study, 
theophylline was studied and detected by ferrocene (Fc) 
redox-labeled  RNA  aptamer.  The  aptamer  was  able  to 
quantify the theophylline in serum and thus proved to 
be an efficient biosensor (Ferapontova & Gothelf, 2009). 
Redox active probes are used in combination with aptam-
ers, and by measuring the changes in their redox states, the 
electrochemical detection is carried out, such as in case 
of thrombin-bound aptamer (Smirnov & Shaffer, 2000). 
Lysozyme detection has been made possible by using an 
aptamer-functionalized silica nanoparticles where once 
the aptamer interacts with the protein, a fluorescence 
Table 2.  Aptamer based detection systems.
S. No. Target Detection system Importance Reference
1. Cocaine Cocaine–aptamer–
aptamer–QD
Detection of cocaine in 
various samples
Freeman (2009); Zhang and Johnson 
(2009)
2. ATP Cellulose-coated  
ATP-binding aptamer
Detection of ATP and 
study of various pathways 
involving ATP
Su et al. (2007)
3. Angiogenin Fluorophore-labeled  
aptamer
Study of tumor  
angiogenesis
Li (2008)
4. C Reactive Protein (CRP) Fluorophore-labeled  
aptamer
Detection of  
inflammation
Centi et al. (2010)
5. Prostate specific 
membrane antigen  
(PSMA)
A10 RNA aptamer-DOX-
SPION
Detection of PSMA in 
prostate cancer
Wang et al. (2008)
6. Histones DNA aptamer and atomic 
force microscopy
Structure and properties  
of histones
Lin et al. (2009)
7. Nucleolus AS1411 aptamer-cobalt  
ferrite nanoparticles in  
silica shell
Cancer cell imaging and 
various purposes
Hwang et al. (2010)
8. Theophylline AuNP with theophylline 
specific aptamer
Detection of theophylline 
and study of asthma
Chavez et al. (2010)
9. Theophylline Ferrocene (Fc) redox  
labeled RNA aptamer
Detection of theophylline 
and study of asthma
Ferapontova and Gothelf (2009)
10. Lysozyme Aptamer functionalized  
silica nanoparticles with 
anionic conjugate polymer
Detection of lysozyme is 
various samples
Wang et al. (2010a)Chimeric aptamers and targeted delivery  469
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signal is emitted by anionic poly(fluorene-alt-vinylene) 
(PFVSO3)  via  electrostatic  interaction.  This  detection 
can be done by naked eye and is a remarkable achieve-
ment in recent trend (Wang et al., 2010a) (Table 2). In 
another work, atomic force microscopy-based imaging of 
nucleosomal arrays was done by acetylation of histones 
at 16th lysine residue and recognized by a DNA aptamer 
specific for histones (Lin et al., 2009).
Hence a lot of work has been done on various targets 
with different types of aptamer chimeras; however, the 
strategy and the parameters considered for their selec-
tion remains quite the same. The most successful and 
commonly  used  aptamer  chimeras  are  the  aptamer–
siRNA chimeras, which have been used extensively to 
target various diseases.
Mechanisms and strategies of delivery of chimeras
It is known that aptamers cannot enter the cell mem-
brane directly by simple diffusion due to their hydropho-
bic nature; hence, various studies have been conducted 
to study the mechanism of entry of aptamer into a cell.
Carrier peptides
Due to the poor permeability and selectivity of the cell 
membrane, there is a need of a strategy that can transport 
aptamers or drugs into large number of cells. The studies 
indicate that the mechanism of endocytosis best explains 
the intracellular trafficking of aptamers. Endocytosis and 
related pathways like classic clathrin-coated pit pathway, 
caveolar  pathway,  clathrin-independent  noncaveolar 
pathway,  macropinocytosis,  and  phagocytosis  are  the 
mechanisms that explain the entry of aptamers in cells 
(Kirkham & Parton, 2005; Perret et al., 2005). The com-
plex flow of endomembrane traffic is regulated by Rab 
family of GTPases and by tethering complexes (Stenmark 
& Olkonnen, 2001), while vesicular fusion phenomenon 
is controlled by SNARE proteins; the sorting nexins (SNX) 
are also important in sorting and cargo retrieval from 
endosomes (Carlton et al., 2005; Van dergoof, 2006; Cai 
et al., 2007). Carrier peptides are small protein domains 
with the ability to cross biological membranes efficiently 
with or without specific receptors to promote the deliv-
ery of desired drug into target cells (Morris et al., 2001).
There are examples where cell targeting ligands (CTLs) 
that  enhance  transmembrane  permeation  have  been 
employed to deliver aptamers (Morris et al., 1997) as there 
is a wide variety of ligands available including antibodies, 
polypeptides derived from phage display libraries, and 
small  organic  molecules  (Hollinger  &  Hudson,  2005). 
Cell penetrating peptides (CPPs) are small peptides of 30 
amino acid residues with a net positive charge which can 
translocate across plasma or endomembranes, transport 
biomacromolecular cargos into cytoplasm and nucleus; 
few examples included are: R9 (arginine 9), MPG pep-
tide, transportan, Tat, penetratin, etc. (Morris et al., 1997; 
Krissansen et al., 2006; Baratchi et al., 2010; Cheung et al., 
2010) Several reports of noncovalent complexes between 
anionic siRNA chain aptamer and cationic CPPs confirm 
that they provided effective delivery to cells in culture 
(Morris et al., 1997; Lundberg et al., 2007).
Nanoparticle systems
Aptamer  technology  has  evolved  in  a  multidirectional 
fashion finding importance and playing essential roles 
in  fields  of  biosensing,  imaging,  drug  delivery,  and 
modern  molecular  medicine  for  therapy  for  various 
diseases and disorders. Taking the advantages of rapidly 
expanding  nanobiotechnology-based  developments; 
aptamer–nanoparticle conjugation forms the basis of a 
new chemical and biological strategy with wide appli-
cation starting from assembly to detection. Because of 
their small size, nanoparticles can interact readily with 
biomolecules both on surface and within the cells and 
thus  they  are  considered  as  a  revolutionary  approach 
for  detection  and  therapy  of  various  diseases.  Various 
conjugation principles have been described leading to 
the application of aptamers in cancer and other inflam-
matory  diseases  as  a  nanodelivery  system  (Kanwar 
et al., 2010c). Since the aptamers are negatively charged 
moieties, the charge of the nanoparticle surface is very 
important for the conjugation between the nanoparticle 
and the aptamers (Farokhzad et al., 2004). Covalent con-
jugation of aptamers to nanoparticles is mainly induced 
by succinimidyl-ester-amine conjugations, whereas, the 
noncovalent  conjugations  include  affinity  interactions, 
metal co-ordinations, surface adsorption, etc. (Farokhzad 
et al., 2005) The conjugation can be quantitatively con-
firmed by various methods, such as flow cytometry, X-ray 
photoemission spectroscopy, Fourier transform infrared 
spectroscopy (FTIR), fluorescent microscopy, etc. (Hicke 
& Stephens, 2000). Interestingly, a chimeric phage RNA 
(pRNA)-aptamer  (specific  to  CD4  antigen  on  T-helper 
cells) conjugate was synthesized and labeled with fluo-
rescein isothyocyanate (FITC) for detection of CD4 and 
with  this  a  trimeric  complex  of  pNA-aptamer  (CD4), 
pRNA-FITC, and pRNA-rhodamine was prepared. Using 
this as a nanocarrier for therapy and diagnosis (Khaled 
et al., 2005), the cellular internalization was studied with 
confocal microscopy. When siRNA was attached to pRNA 
trimer complex for silencing the CD4 surface receptor’s 
gene expression, a decrease in CD4 expression in FITC 
positive cells was observed (Khaled et al., 2005). Another 
work  comprised  of  synthesis  of  polylactic  acid  (PLA)-
polyethyleneglycol (PEG) copolymers incorporated with 
paclitaxel (ptxl). The ptxl was incorporated into the PLA-
PEG copolymer which was then attached to A10 PSMA 
aptamer with 5´-NH2 modifications and was tested for 
successful uptake in human prostate cancer cells (LNCAP 
and PC3) (Tong et al., 2010). The A10 RNA aptamer with 
2´-F  (fluoropyrimidine)  modification  was  tagged  to 
poly(lactide-co-glycolide) (PLGA) as a model-controlled 
release polymer system and PEG (a model hydrophilic 
polymer  with  anti-biofouling  properties),  to  develop 
a  triblock  copolymer  comprising  of  PLGA-PEG-A10 
aptamer, which is a targeted nanodelivery system (GU 
et al., 2008).470  J.R. Kanwar et al.
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Nanocapsule-based targeted multidrug delivery
Most  of  these  methods  are  well  characterized  and 
ensure appropriate detection of the desired molecule. 
Yet,  modern  developments  are  able  to  show  light  on 
the  drawbacks  of  current  methods.  Nanocarriers  are 
vehicles mainly used for drug delivery to enhance the 
stability and to prolong the circulation of the drug in the 
target tissue by promoting their permeability and reten-
tion. There are several drawbacks of nanocarriers, such 
as their limited drug loading capacity, difficulty in track-
ing the movement of the drug, imaging and diagnosis, no 
real-time diagnostics, lack of pH, and thermal stability. 
All these factors lead to lack of knowledge of mechanism 
of drug uptake by the cells. The mechanism of internal-
ization of nanocarrier into target cells mainly depends 
on  physiochemical  property  of  the  nanocarrier  itself. 
Thermal stability and pH of nanocarrier are keys and 
essential factors for appropriate drug delivery. Over the 
time, it is evident that nanocarriers have a great poten-
tial in drug delivery. The need is to exploit, optimize, 
and enhance the intracellular and subcellular delivery 
of  drugs,  which  are  unstable  or  stable  in  physiologi-
cal conditions to the target site. There is also a need to 
develop a multidrug nanocarrier for delivery of specific 
drugs for diverse functions in a particular or in various 
target  sites.  Recently  multifunctional  nanocapsules 
have emerged that are capable of providing therapy and 
diagnosis in real time (Figure 4). These nanocapsules are 
portable and thus can be used on and off the field; they 
possess thermal stability, pH sensibility and are capable 
of carrying several different drugs at the same time. They 
are equipped with a camera for real-time imaging. Such 
efficiency will help to study the intracellular fate of the 
various drugs as well as real-time imaging and monitor-
ing  them.  These  drugs  can  be  monitored  distantly  as 
well by means of satellite by more than one personnel 
in different places at the same time. The release of drug 
can be monitored well through the computed systems 
and once the nanocapsules reach the target the valves 
can  be  opened  in  order  to  release  the  drugs.  Use  of 
biodegradable nanocapsules will minimize the chance 
of drug toxicity and size of nanocapsules can be regu-
lated considering the amount of drug to be loaded. The 
aptamer will bind to the target due to its high specificity, 
whereas the other drugs will bind to their respective tar-
get due to expression of various markers and receptors. 
This development will increase the possibility of target-
ing the nanocarriers to the desired cells and to study 
Figure 4.  Representation of future generation drug delivery by means of nanocapsules that are equipped with real-time imaging and 
wireless monitoring chips. These nanocapsules can be loaded with several drugs at the same time, and can be taken orally due to lack of 
any toxic effects. Once present in intestine the nanocapsules can be monitored by the controlling system to release the drugs by opening 
the valves. The drugs can act specifically on the respective target sites due to presence of various receptors and thus multiple diseases can 
be targeted at the same time and can be monitored as well in real time. These drugs can be monitored by means of satellite at different 
places simultaneously hence providing better diagnosis by the experts (Huertas et al., 2010; Shen et al., 2010). (See colour version of this 
figure online at www.informahealthcare.com/bmg)Chimeric aptamers and targeted delivery  471
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the nanocarrier cell interaction (Hillaireau & Couvreur, 
2009;  Huertas  et  al.,  2010;  Shen  et  al.,  2010;  Wang  &   
Ho, 2010b).
Multitargeted LNA-aptamer complexes with anticancer-
loaded iron-saturated bovine lactofeerin dopamine surface 
modified Fe3O4 nanoparticles for specific killing of tumor cells
We showed that 100% iron-saturated bovine lactofeerin 
(Fe-bLf) acts as a potent natural adjuvant and fortifying 
agent for augmenting cancer chemotherapy with broad 
utility in the treatment of cancer (Kanwar et al., 2008). 
The key findings of the study revealed: (i) Fe-bLf bound 
to the intestinal epithelium and was preferentially taken 
up within Peyer’s patches(Figure 2); (ii) Fe-bLf enhanced 
antitumor activity in combination with major antican-
cer drugs (paclitaxel, doxorubicin, epirubucin, or flur-
ouracil), the combination being capable of completely 
eradicating large tumors of EL4 lymphoma, Lewis lung 
carcinoma, B16 melanoma (0.6 cm diameter) that were 
otherwise completely insensitive to chemotherapy; (iii) 
Natural  bLf,  4%  iron-saturated  or  50%  iron-saturated 
bLf  were  less  effective  at  potentiating  cancer  chemo-
therapy, and did not cause tumor eradication; (iv) Fe-bLf 
increased  the  production  of  Th1  and  Th2  cytokines 
within the intestine and tumor, including TNF-α, IFN-γ, 
as well as nitric oxide (NO) that have been reported to 
sensitize  tumors  to  chemotherapy;  (v)  Fe-bLf  almost 
completely  reduced  tumor  vascularity  (angiogenesis) 
and  blood  flow,  and  increased  tumor  apoptosis  regu-
lated by survivin, Bcl-2, caspases 9/3, and Fas molecules; 
(vi) Fe-bLf increased leukocyte infiltration (CD4+,CD8+, 
NK, and dendritic cells) to tumors, lamina propria, and 
spleen; and (vii) importantly, Fe-bLf restored both red 
(RBC)  and  white  (WBC)  blood  cell  numbers  depleted 
by chemotherapy, potentially fortifying the mice against 
cancer (Kanwar et al., 2008; Gibbons et al., 2011; Kanwar 
RK et al., 2011). The Fe-bLf was prepared (Kanwar et al., 
2008). Superparamagnetic iron oxide (Fe3O4) nanopar-
ticles  (SPIONs),  which  are  nontoxic,  biodegradable, 
inexpensive and candidate platforms for the build-up of 
theranostic nanostructures were prepared as described 
(Xie et al., 2010, Soundararajan et al., 2008). Here, we 
used  dopamine  to  modify  the  surface  of  SPIONs  for 
yielding nanoconjugates that can be easily encapsulated 
into  anticancer  Fe-bLf  protein.  These  nanocarrier  sys-
tems were well-suited for dual encapsulation of SPIONs 
for imaging or monitoring therapy and drug molecules, 
because the encapsulation or conjugation is achieved in 
a way that is similar to common drug loading. The LNA-
nucleolin DNA aptamer (molecule present on cancer cell 
surfaces  and  translocated  to  nucleus)  (Soundararajan 
et  al.,  2008)  and  LNA-EpCAM  RNA  aptamer  (Shigdar 
et al., 2011), known to be over-expressed on the apical 
side of the cancer cell surfaces were prepared (Hertoghs 
et al., 2003) and loaded individually or in combination 
on these Fe-bLf-SPOINS nanocarriers. The average size 
of the nanocarriers in various steps of their preparations 
were found to be (170 ± 35 nm) as determined by dynamic 
light  scattering  (DLS),  scanning  electron  microscopy 
(SEM),  and  transmission  electron  microscopy  (TEM), 
Fourier transform infrared spectroscopy (FTIR), differ-
ential  scanning  calorimeter  (DSC),  thermogravimetric 
analysis (TGA), and X-ray diffraction (XRD). These LNA-
aptamers-loaded Fe-bLf nanocarriers were treated with 
human cancer cell line Caco-2 (human colon cancer), 
MDA-MB  231  (human  breast  cancer),  normal  HMECs 
(human mammary epithelial cells), and normal FHs 74 
Int (an adherent human primary fetal small intestinal) 
cell  lines  obtained  from  the  American  Type  Culture 
Collection (ATCC, USA). These LNA-aptamer complexes 
of  Fe-bLf  nanocarriers  induce  massive  cell  death  in 
breast and colon cancer cells in vitro and spare normal 
HMECs and FHs 74 Int cells in an in  vitro co-culture 
model (Figure 5A and B). A rotational magnetic field fre-
quency of 1Hz has shown a maximum amount of LDH 
release or cytotoxicity and cell death through apoptosis 
measured by Tunnel and Annexin-V positive cells com-
pared to normal cells (Kanwar et al., 2001; Kanwar et al., 
2008). After applying magnetic field with 1Hz, we found 
that the cancer cells massively increased in breast and 
colon as compared to normal HMECs and normal FHs 
74  Int  cell  lines  (data  not  shown).  This  indicates  that 
SPIONs-loaded LNA-aptamers have the potential to kill 
cancer cells more specifically, effectively, and spare nor-
mal cells. We evaluated the tissue biodistribution of these 
nanocarriers  using  a  fluorescent  marker,  6-coumarin 
and the fluorescent quantum yield characters enabled 
the selective tracking of the in vivo distribution of nano-
capsule (Woodrow, 2009) (Figure 5C). These signals were 
captured by magnetic sensors and release of the Fe-bLf 
-loaded LNA-aptamers from nanocarriers was monitored 
on computer from outside (unpublished information). 
The release of nanocarriers can be controlled in in vivo 
situations not only in human gut associated microbial 
(parasitic or viral or bacterial) infections, inflammations, 
and  cancers  but  also  anywhere  in  the  body  by  LNA-
aptamers  targeting  nanocarriers  (Figure  4).  Thus,  we 
developed LNA-modified nucleolin aptamers and LNA-
modified EpCAM aptamers conjugated “Fe-bLf natural 
anticancer  protein-loaded  nanobullet  nanocarriers,” 
which specifically target cancer cells and spare normal 
cells. Hence, we developed natural nanomedicinal-based 
war against cancer cells with targeted nanobullet nano-
carriers  that  specifically  induce  their  traumatic  death 
and spare normal cells. Superparamagnetic iron oxide 
(Fe3O4) nanoparticles (SPIONs) nature of these nanocar-
riers was used to monitor the size of tumors in the treated 
mice through different imaging systems such as in vivo 
positron emission tomography (PET)/near-infrared fluo-
rescence (NIRF)/magnetic resonance imaging (MRI) for 
future potential contrast material for cancer diagnosis as 
described earlier (Xie et al., 2010).
Aptamers in clinical trials
With new developments in nanotechnology and chem-
istry, few aptamers have found their way into modern 472  J.R. Kanwar et al.
  Critical Reviews in Biochemistry and Molecular Biology
Figure 5.  Cell cytotoxicity determined by LDH release assay and cell death (apoptosis) by TUNEL assay of (A) breast cancer cells and 
(B) colon cancer cells and compared with normal cells following treatment with 1600 μg/mL of iron saturated lactoferrin (Fe-bLf) and 
other control nanoformulations and control aptamers (nucleolin and EpCAM). Cells were treated for 24 h with different nanoformulations 
and stained by TUNEL analysis for apoptotic cells. Cell death is shown here in terms of apoptotic (% apoptosis) and LDH release (% 
cytotoxicity). All treatments were performed in triplicate and assay was repeated three times independently with similar results. The mean 
for representative experiment was calculated and presented as a mean ± SD values; ** indicates a highly significant p < 0.001 value from 
the normal control cell lines and with media only; * indicates a significant p < 0.05 value from the normal control cell lines and control with 
media only, (C) Biodistribution study of nanocarriers compared with Fe-bLf in oral administrations. Fluorescent signal of tissue extracts 
after 36 h of oral administration. Nanocarriers were labeled with coumarin (10mg/mL).Chimeric aptamers and targeted delivery  473
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medicine.  The  pharmaceutical  industries  are  ready  to 
invest more on recent nano-aptamer technology which 
has  added  benefits  when  compared  to  the  traditional 
drugs.  In  a  very  short  span  of  time,  aptamers  have 
attained  critical  importance  in  the  field  of  modern 
molecular medicine and nanomedicine. Several aptam-
ers are in clinical trial such as, EYE001 targeting vascular 
endothelial  growth  factor  receptor  (VEGFR);  phase  II/
III (Carrasquillo et al., 2003). Edifoligide aptamer which 
is used to treat vein graft failure of heart and leg; phase 
III (C. Inc, 2004). The E100300 to target platelet derived 
growth  factor  (PDGF)  (phase  II)  (JO  et  al.,  2006).  The 
Nu172 to target thrombin; phase II (Wagner-Whyte et al., 
2007), REG1, which targets factor IXa; phase IIb (Becker, 
2009), ARC1779, which inhibits the acute coronary syn-
dromes  by  preventing  the  binding  of  platelet  receptor 
glycoprotein Ib to its receptor; phase I/II (ClinicalTrials.
gov, 2009), AS1411, which is being used to treat cancer by 
inhibiting their DNA replication; phase III (Stuart et al., 
2009),  ARC1905,  which  prevents  age-related  macular 
degeneration (AMD); phase I (ClinicalTrials.gov, 2010), 
LY2181308,  which  is  used  in  treatment  of  nonsmall 
cell lung cancer (NSLC); phase III (Cancerhelp.org.uk, 
2010), and many others. However, macugen was the first 
aptamer to get the FDA approval in 2004 for treatment of 
wet AMD (NG et al., 2006).
conclusion
Various  chimeras  such  as  aptamer–aptamer,  aptamer–
siRNA,  aptamer–miRNA,  aptamer–enzyme,  aptamer–
antibody, and aptamer–NRTI have been established. All 
of these chimeras show better stability and functional 
capability than the parent molecules used to form the 
chimera. Several methodologies have been established 
to produce and select the chimeras based on their speci-
ficity such as chimeric SELEX. Specific delivery of chi-
meric aptamers has been achieved by their conjugation 
with various nanoparticles and according to the nature 
of  nanoparticles  or  the  modifications  in  the  aptamer 
chimeras and can be used for imaging and diagnosis. 
Aptamer chimerism offers a wide range of activity due 
to the presence of two molecules playing two or more 
different roles simultaneously. They have an additional 
advantage over the existing methodology and are highly 
stable, more flexible with various types of modifications, 
and cost effective. Since aptamers are nonimmunogenic, 
most of the aptamer chimerics can be expected to be less 
or  nonimmunogenic.  Aptamer  chimerics  have  various 
applications, such as tumoricidal activity, detection of 
small analytes, HIV inhibitory properties and detection 
of  pathogens  in  food  samples,  personalized  drug  and 
vaccine  development  against  parasites,  bacterial,  and 
viral agents, targeting cancer cells at a subcellular level, 
such as the cell organelles, and targeting different cel-
lular  cascade  pathways.  Well-characterized  chimerics 
can be brought into therapeutic use for various inflam-
matory disorders as well. Because aptamer chimeras can 
be generated for several biomarkers and receptors, they 
offer a better specificity, target recognition, and improved 
therapeutics than any antibodies or synthetic peptides. 
Recently,  various  drug  delivery  and  imaging  systems 
have  been  developed  which  can  be  further  improved 
with the help of aptamer chimerics. Nanocapsules with 
modern technologies for real-time imaging can be used 
to monitor the interaction between the aptamer chime-
ras and target cells. Multivalent nanoparticles, such as 
dendrimers with high potential for performing several 
functions simultaneously can be developed by the use of 
chimeric aptamers. Thus, aptamer chimeras may prove 
to be useful in future for a wide range of diseases.
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